CSIMarket
 
Plus Therapeutics Inc   (PSTV)
Other Ticker:  
 
 
Price: $1.7200 $-0.01 -0.578%
Day's High: $1.7646 Week Perf: -2.82 %
Day's Low: $ 1.67 30 Day Perf: -13.57 %
Volume (M): 23 52 Wk High: $ 5.09
Volume (M$): $ 40 52 Wk Avg: $2.01
Open: $1.75 52 Wk Low: $0.21



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Plus Therapeutics Inc
Plus Therapeutics Inc is a biotechnology company that specializes in developing and commercializing innovative, targeted therapies for rare and difficult-to-treat cancers. Their focus is on creating novel drugs that can potentially improve outcomes for patients with limited treatment options. They aim to combine advanced drug delivery technologies with cutting-edge science to deliver more effective and personalized treatments.


   Company Address: 4200 MARATHON BLVD AUSTIN 78756 TX
   Company Phone Number: 255-7194   Stock Exchange / Ticker: NASDAQ PSTV
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Plus Therapeutics Announces Completion of Dosing in Cohort 5 of Groundbreaking Phase 1 Trial on Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases

Published Mon, Mar 11 2024 11:00 AM UTC

Plus Therapeutics, a leading pharmaceutical company, has successfully achieved a significant milestone in its groundbreaking clinical trial investigating the efficacy of Rhenium (186Re) Obisbemeda for the treatment of Leptomeningeal Metastases (LM). Following the completion of dosing in Cohort 5, a total of 18 patients have been enrolled in the trial so far, marking an impor...

Partnership

Plus Therapeutics and K2bio Partner to Revolutionize CSF Cancer Testing for ReSPECT-LM Patients

Published Tue, Dec 12 2023 1:01 PM UTC



In a groundbreaking collaboration, Plus Therapeutics has joined forces with K2bio to develop innovative tests for the analysis of cerebrospinal fluid (CSF) tumor cells and molecular biomarkers. This partnership aims to explore novel CSF cancer testing modalities, offering hope for improved diagnostics and personalized treatment options. With an initial testing pane...

Plus Therapeutics Inc

Phenomenal Growth: Plus Therapeutics Inc. Witnesses Spectacular 1598.63% Surge in Revenue in Q3 2023

Article: Plus Therapeutics Inc's Robust Revenue Growth Outpaces Industry Peers
Plus Therapeutics Inc has reported impressive financial results for the third quarter of 2023, with a significant revenue advance of 1598.63% year on year to $1.24 million. However, the company also experienced a shortfall per share of $-1.00. This robust revenue growth outperformed most companies in the Medical Equipment & Supplies sector, which only saw a revenue advance of 0.77% in the same period compared to the third quarter of 2022.
In contrast to the substantial revenue growth, Plus Therapeutics Inc also saw an increased shortfall from $-0.59 per share in the previous reporting period, as well as a significant decline in revenue by -33.118% from $1.85 million. The company reported a net shortfall of $-3.219 million from July to September 2023, an improvement from the $-5.219 million deficit in the same period last year.

Shares

Plus Therapeutics Empowers Shareholders with a Strategic Share Repurchase Program

Published Tue, Oct 31 2023 8:10 PM UTC



Plus Therapeutics, Inc. (Nasdaq: PSTV), a leading clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system cancers, has announced its Board of Directors' approval of a comprehensive share repurchase program. With authorization to repurchase up to $500,000 of the company's outstanding common stock, this strategic mo...

Plus Therapeutics Inc

Plus Therapeutics Inc Reports Impressive Revenue of $1.854 Million, Achieves Remarkable Decrease in Deficit - Growth and Financial Success Continues in Q2 2023!

Financial News Report: Plus Therapeutics Inc Reports Positive Revenue and Decreased Deficit in Q2 2023; Stock Performance Remains Strong
Plus Therapeutics Inc, a prominent Medical Equipment & Supplies company, has recently disclosed its financial results for the April to June 30, 2023 financial timeframe. The company reported $1.854 million in revenue during this period, showcasing positive growth in comparison to the corresponding reporting period last year.
Notably, Plus Therapeutics Inc achieved a significant milestone by improving its financial position. In the April to June 30, 2023 reporting period, the company reported a net deficit of $-1.482 million, marking a notable decrease from the deficit of $-5.282 million reported during the same period in the previous year. This reduction in deficit reflects positive financial management and strategic decision-making by the company's management.






 

Plus Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com